News & Events – Page 2 – Sumitovant

Select Company

September 09, 2021Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
September 01, 2021Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
August 12, 2021Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
July 28, 2021Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
July 20, 2021Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
July 14, 2021Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
June 01, 2021Myovant Sciences to Present at Upcoming Investor Conferences
May 26, 2021Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 21, 2021Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 12, 2021Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
« Previous 1 2 3 4 … 9 Next »